Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 103, Issue 8, Pages 822-831Publisher
WILEY
DOI: 10.1002/jso.21787
Keywords
peritonectomy; hyperthermic intraperitoneal chemotherapy (HIPEC); receptor tyrosine-kinase; telomerase; EGFR
Funding
- Italian Association for Cancer Research (AIRC)
- Italian Health Ministry
Ask authors/readers for more resources
Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving. J. Surg. Oncol. 2011; 103:822-831. (C) 2011 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
